Damien Roos-Weil, MD, PhD

Pitié-Salpêtrière Hospital, France

Poster(s):

• 1521 - Real-world efficacy and safety of venetoclax +/- rituximab in >75-years old patients or with cardiovascular comorbidities and R/R chronic lymphocytic leukemia: interim results of the VERONE study

• 1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study